Analysts Set Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Target Price at $7.00

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) has received a consensus rating of “Moderate Buy” from the six brokerages that are covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $5.50.

A number of analysts have recently weighed in on the stock. Truist Financial raised shares of Sangamo Therapeutics from a “hold” rating to a “buy” rating and set a $7.00 price target for the company in a research report on Friday, December 13th. HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of Sangamo Therapeutics in a report on Thursday. Wells Fargo & Company cut their target price on shares of Sangamo Therapeutics from $3.00 to $2.00 and set an “equal weight” rating on the stock in a research note on Tuesday, December 31st. Jefferies Financial Group reduced their price target on shares of Sangamo Therapeutics from $7.00 to $3.00 and set a “buy” rating on the stock in a research report on Tuesday, December 31st. Finally, StockNews.com lowered Sangamo Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, December 24th.

Sangamo Therapeutics Price Performance

Shares of Sangamo Therapeutics stock opened at $1.30 on Tuesday. Sangamo Therapeutics has a 1-year low of $0.30 and a 1-year high of $3.18. The company has a market capitalization of $271.24 million, a PE ratio of -1.73 and a beta of 1.15. The business has a 50-day moving average of $2.13 and a 200-day moving average of $1.24.

Sangamo Therapeutics (NASDAQ:SGMO) last issued its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported $0.04 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.07. Sangamo Therapeutics had a negative return on equity of 264.16% and a negative net margin of 257.87%. The firm had revenue of $49.41 million during the quarter, compared to analyst estimates of $26.55 million. During the same quarter last year, the firm earned ($0.34) EPS. On average, equities analysts expect that Sangamo Therapeutics will post -0.46 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Sangamo Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the business. Virtu Financial LLC acquired a new position in Sangamo Therapeutics in the third quarter valued at approximately $150,000. Geode Capital Management LLC boosted its position in Sangamo Therapeutics by 14.6% during the 3rd quarter. Geode Capital Management LLC now owns 2,138,309 shares of the biopharmaceutical company’s stock valued at $1,853,000 after purchasing an additional 272,123 shares during the period. XTX Topco Ltd grew its stake in Sangamo Therapeutics by 167.8% during the 3rd quarter. XTX Topco Ltd now owns 103,716 shares of the biopharmaceutical company’s stock worth $90,000 after buying an additional 64,981 shares during the last quarter. State Street Corp increased its position in Sangamo Therapeutics by 28.0% in the third quarter. State Street Corp now owns 664,621 shares of the biopharmaceutical company’s stock worth $576,000 after buying an additional 145,400 shares during the period. Finally, FMR LLC increased its position in Sangamo Therapeutics by 16.5% in the third quarter. FMR LLC now owns 544,003 shares of the biopharmaceutical company’s stock worth $471,000 after buying an additional 77,032 shares during the period. Institutional investors and hedge funds own 56.93% of the company’s stock.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.